A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost.
Rheumatoid arthritis (RA) is a chronic auto-immune disease that causes pain and stiffness in the joints, fatigue, bone damage and, eventually, loss of mobility. RA afflicts around 1% of people in the western world; in Belgium, 80,000 to 100,000 people currently live with the disease.
Because there is no known cure for RA, physicians focus treatment on suppressing disease activity. Therapies have improved in recent years, and clinical studies show that intensive treatment of early RA can prevent joint damage and improve patients’ quality of life.
In the two-year study, called ‘CareRA’ (Care in early RA), researchers and clinicians in the rheumatology unit at University Hospitals Leuven examined various therapies for early RA. Their goal: to find the optimal combination and dosage of three commonly prescribed antirheumatic drugs (methotrexate, sulfasalazine and leflunomide) in combination with glucocorticoids (a class of steroid hormones).
The researchers divided 290 early RA patients into three treatment groups. Each group received a different combination therapy: ‘COBRA Classic’ (methotrexate, sulfasalazine and a high first dose of glucocorticoids), ‘COBRA Slim’ (methotrexate and a moderate dose of glucocorticoids) or ‘COBRA Avant-Garde’ (methotrexate, leflunomide and a moderate dose of glucocorticoids).
Fewer side effects
All three strategies showed a similarly high efficacy: disease remission was achieved in 7 in 10 patients after 16 weeks of treatment. But results for the strategies varied significantly when it came to side effects.
The new COBRA Slim strategy, which calls for the least amount of medication, had half as many side effects as the two other strategies – and was just as effective. The strategy would also be easier to implement in daily practice because it is less complicated.
A broader use of this strategy would lead to higher remission rates in the global early RA population and would probably reduce the need for expensive second-line antirheumatic treatment, say the researchers.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- 8 Things I Want You to Understand About Living With Rheumatoid Arthritison July 5, 2019 at 4:54 pm
I’ve been living with a diagnosis of rheumatoid arthritis (RA) for two-and-a-half years, but looking back, I probably had RA for much longer than that. Since my diagnosis, I’ve had a significant ... […]
- How I Explain Rheumatoid Arthritis to Those Don't Have Iton July 5, 2019 at 1:17 pm
How can I begin explaining the confusing, illusive and invisible debilitating autoimmune disease known as rheumatoid arthritis? My name is Eileen Davidson. I am a 33-year-old female from Vancouver B.C ... […]
- GSK Advances Arthritis Candidate into Phase III, Triggering €22M Milestone Payment to MorphoSyson July 5, 2019 at 5:43 am
GlaxoSmithKline (GSK) has launched a Phase III program for the rheumatoid arthritis candidate it is developing under license from MorphoSys—triggering a milestone payment to MorphoSys of €22 million ... […]
- Rheumatoid arthritis symptoms: Having this temperature in your joints must NOT be ignoredon July 4, 2019 at 11:04 am
Arthritis is a type of inflammatory autoimmune disease and is a musculoskeletal condition which is caused by the body’s joints. The areas most commonly affected include the hands, fingers, hips, knees ... […]
- Gilead to seek FDA approval for rheumatoid arthritis drug this yearon July 2, 2019 at 10:04 am
A U.S. biotech company plans to seek Food and Drug Administration approval for a drug to treat autoimmune diseases this year. Foster City, California-based Gilead Sciences said Monday that it ... […]
- Health Care Digest: Gilead's big plan for rheumatoid arthritis, Gladstone's new heart chief, Chan Zuckerberg's cell atlas and moreon July 2, 2019 at 4:58 am
Our health care digest features a roundup of local news items, insights from other publications and must-reads from our own newsroom. We'd love to hear what you think and how we can improve. Please ... […]
- After Hours: Sarin Scare at Facebook, Gilead to Make Arthritis Drug Submission Soonon July 1, 2019 at 6:13 pm
Following these discussions, Gilead stated that "a path forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 2019." Gilead previously said it ... […]
- Velcro sound detector accurately identifies ILD in rheumatoid arthritison July 1, 2019 at 7:53 am
An algorithm designed to detect Velcro crackles in the lungs demonstrated diagnostic accuracy for detecting interstitial lung disease in patients with rheumatoid arthritis, according to a study ... […]
- United States Rheumatoid Arthritis Market and Competitive Landscape, 2014-2018 & 2019-2024 - ResearchAndMarkets.comon July 1, 2019 at 2:10 am
The "US Rheumatoid Arthritis Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering. United States Rheumatoid Arthritis Market and Competitive ... […]
- Rheumatoid Arthritis Drugs Market in Global : Current and the Future Trendson June 28, 2019 at 9:40 am
Jun 28, 2019 (Hitech News Daily via COMTEX) -- Global Rheumatoid Arthritis Drugs/Therapeutics Market valued approximately USD 22.14 billion in 2018 is anticipated to grow with a healthy growth rate of ... […]
via Bing News